Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 20/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 20/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 10/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 8/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4886755 | 0.93 | CYP3A4 (0.82) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL6349099 | 0.91 | CYP3A4 (0.70) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL3274522 | 0.90 | CYP3A4 (0.74) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL2368041 | 0.89 | CYP3A4 (0.68) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL1816215 | 0.89 | CYP3A4 (0.86) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL31706363 | 0.87 | CYP3A4 (0.70) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL4161190 | 0.86 | CYP3A4 (0.80) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL14290065 | 0.85 | CYP3A4 (0.68) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL20987042 | 0.84 | CYP3A4 (0.61) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| Linaprazan SCHEMBL1138353 | 0.84 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025215593-A1 | AN IMPROVED PROCESS FOR PREPARATION OF ZASTAPRAZAN | HETERO LABS LIMITED (IN) | 2025-10-16 | — | — | WO | claimed |
| WO-2025215593-A1 | AN IMPROVED PROCESS FOR PREPARATION OF ZASTAPRAZAN | HETERO LABS LIMITED (IN) | 2025-10-16 | — | — | WO | disclosed |
| WO-2025215593-A1 | AN IMPROVED PROCESS FOR PREPARATION OF ZASTAPRAZAN | HETERO LABS LIMITED (IN) | 2025-10-16 | — | — | WO | disclosed |
| US-20090247755-A1 | Process for Preparing a Substituted Imidazopyridine Compound | ELMAN BJORN | 2009-10-01 | — | — | US | disclosed |
| US-20090247755-A1 | Process for Preparing a Substituted Imidazopyridine Compound | ELMAN BJORN | 2009-10-01 | — | — | US | disclosed |
| US-20090247755-A1 | Process for Preparing a Substituted Imidazopyridine Compound | ELMAN BJORN | 2009-10-01 | — | — | US | disclosed |
| US-20060063797-A1 | Process for preparing a substituted imidazopyridine compound | ELMAN BJORN | 2006-03-23 | — | — | US | disclosed |
| EP-1073657-B1 | IMIDAZO PYRIDINE DERIVATIVES WHICH INHIBIT GASTRIC ACID SECRETION | ASTRAZENECA AB (SE) | 2005-12-07 | — | — | EP | disclosed |
| US-6900324-B2 | Process for preparing a substituted imidazopyridine compound | ASTRAZENECA AB (SE) | 2005-05-31 | — | — | US | disclosed |
| EP-1317455-B9 | PROCESS FOR PREPARING A SUBSTITUTED IMIDAZOPYRIDINE COMPOUND | ASTRAZENECA AB (SE) | 2004-11-17 | — | — | EP | disclosed |
| EP-1317455-B1 | PROCESS FOR PREPARING A SUBSTITUTED IMIDAZOPYRIDINE COMPOUND | ASTRAZENECA AB (SE) | 2004-08-04 | — | — | EP | disclosed |
| US-20040039013-A1 | Process for preparing a substituted imidazopyridine compound | ASTRAZENECA AB (SE) | 2004-02-26 | — | — | US | disclosed |
| EP-1317455-A1 | PROCESS FOR PREPARING A SUBSTITUTED IMIDAZOPYRIDINE COMPOUND | AstraZeneca AB (SE) | 2003-06-11 | — | — | EP | disclosed |
| WO-2002020523-A1 | PROCESS FOR PREPARING A SUBSTITUTED IMIDAZOPYRIDINE COMPOUND | ASTRAZENECA AB (SE) | 2002-03-14 | — | — | WO | disclosed |
| US-6313137-B1 | FOR THERAPY AND PROPHYLAXIS OF GASTROINTESTINAL INFLAMMATORY DISEASES | ASTRAZENECA AB (SE) | 2001-11-06 | — | — | US | disclosed |
| WO-1999055706-A9 | IMIDAZO PYRIDINE DERIVATIVES WHICH INHIBIT GASTRIC ACID SECRETION | ASTRA AB (SE) | 2000-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063797-A1 | Process for preparing a substituted imidazopyridine compound | NISCH, CYP1B1, CYP1A2 | CYP3A4 8/4885CYP2C9 121/4885CYP2D6 24/4885 |
| US-20090247755-A1 | Process for Preparing a Substituted Imidazopyridine Compound | NISCH, CYP1A2, CYP1B1 | CYP3A4 13/4885CYP2C9 133/4885CYP2D6 23/4885 |
| US-20040039013-A1 | Process for preparing a substituted imidazopyridine compound | CYP1B1, BRD1, SKP1 | CYP3A4 24/4885CYP2C9 261/4885CYP2D6 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.